The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Avadel Pharmaceuticals plc(NASDAQ:AVDL) 
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. T...
Website: http://www.avadel.com
Founded: 1990
Full Time Employees: 50
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
Avadel Pharmaceuticals plc Days Payable Outstanding ttm (DPO)
Avadel Pharmaceuticals plc Days Receivable Outstanding ttm (DSO)
Avadel Pharmaceuticals plc Days Inventory Outstanding ttm (DIO)
Avadel Pharmaceuticals plc Op Cashflow Per Share ttm
Avadel Pharmaceuticals plc Free Cashflow Per Share ttm
Avadel Pharmaceuticals plc Cash Per Share ttm
Avadel Pharmaceuticals plc P/S ratio ttm
Avadel Pharmaceuticals plc (GAAP) P/E ratio ttm
Avadel Pharmaceuticals plc P/B ratio ttm
No extra charts and metrics for this ticker.